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With the human genome product and continuing advances in molecular biology many therapeutic
genes have been discovered. In the cardiovascular system, gene therapy has the potential to improve
myocardial vascularization and ameliorate congestive heart failure. For successful development of
clinical gene therapy, however, effective gene delivery vectors are needed. Ultrasound contrast agents
can be used to develop new, more effective vectors for gene delivery. Ultrasound contrast agents lower
the threshold for cavitation by ultrasound energy. Using physical properties of microbubbles and
coating materials, genetic drugs have been incorporated into ultrasound contrast agents. Gene-
bearing microbubbles can be injected IV and ultrasound energy applied to the target region. As the
microbubbles enter the region of insonation, the microbubbles cavitate, locally releasing DNA.
Cavitation also likely causes a local shockwave that improves cellular uptake of DNA. With trans-
thoracic ultrasound, using commercially available diagnostic ultrasound system and an IV injection
of gene-bearing microbubbles, high levels of transgene expression are observed in the insonated
region of the myocardium. This new technology using microbubbles and ultrasound for gene delivery
merits further study and development. (ECHOCARDIOGRAPHY, Volume 18, May 2001)
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Gene delivery is under development to treat
a variety of human diseases. In the cardiovas-
cular system, encouraging results are being ob-
tained with the gene for vascular endothelial
growth factor (VEGF).1 Gene therapy with
VEGF has been shown in animal studies as
well as clinical trials to increase angiogenesis
(new vessel formation) in ischemic tissue. An-
giogenesis has therapeutic benet to improve
vascularization in the setting of decreased
blood ow to atherosclerosis. Therapeutic ben-
ets have been shown in the myocardium for
coronary artery disease and in the extremities
for peripheral vascular disease.1,2 Vascular
thrombosis has been moderated by using ad-
enoviral transfer of genes for anticoagulant
proteins such as hirudin.3 Future antithrom-
botic targets for gene therapy include nitric
oxide synthase,4 cyclooxegenase, and prostacy-
cline synthase for antiplatelet activity, TFPI
for anticoagulant activity, and tPA or uPA for
brinolytic activity.5
Vascular disease is an important target for
developing gene transfer strategies. Delivery of
the genes to the desired vascular tissue, how-
ever, can be difcult to achieve. Delivery of the
VEGF gene has generally required direct injec-
tion of the genetic material into the tissue.6 In
the extremities, this can be achieved by direct
injection of the plasmid DNA encoding the
VEGF gene into the muscle.2 In the heart this
is more difcult and requires an invasive pro-
cedure to introduce the genetic material into
the myocardial procedure. Surgical exposure of
the heart has been used to open a window for
direct injection of the VEGF gene into the myo-
cardial tissue.6,7 Another possible approach is
via catheter delivery into the coronary arteries,
but this has been less effective than direct in-
jection.
For a therapeutic gene to be effective, it must
reach the target cells, enter the nucleus of
these cells, and then the gene must be ex-
pressed.8 Gene expression and production of a
protein product are generally necessary to pro-
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duce therapeutic effects.9 In the case of VEGF,
the gene must be transcribed, and from the
messenger RNA, the VEGF protein translated.
Therapeutic angiogenesis can be achieved with
VEGF protein directly without the gene.10 The
advantage of using the gene instead, however,
is that a more prolonged therapeutic effect can
be achieved. While one molecule of VEGF pro-
tein may only act for a short while before it is
metabolized, the gene may continue to produce
VEGF for as long as the gene is transcribed.
New ultrasound contrast agents have been
developed and some of these are now FDA ap-
proved.11-13 This article explores some of the
potential applications of ultrasound contrast
agents for gene delivery. We shall attempt to
explain how ultrasound contrast agents can be
used for targeted localized gene delivery. These
agents have applications for delivering genetic
material such as VEGF for treating ischemic
cardiovascular disease and other gene products
for treating other diseases such as cancer and
arthritis.
Applications of Ultrasound Contrast
Agents in Gene Delivery
Briey, let us consider the barriers to effec-
tive gene delivery. Therapeutic genes are mac-
romolecules with several thousand base pairs
and molecular weights over 1 million Dal-
tons.14 These materials generally are relatively
rapidly metabolized by serum esterases and
are, therefore, not stable to IV administration,
unless the genetic material is stabilized in
some fashion.15 Genes, like macromolecules,
are generally too large to pass across the cap-
illary fenestrations of blood vessels unless as-
sisted by some mechanism. For systemic deliv-
ery, the large size of genes is then an obstacle
to delivery to tissues beyond the endothelial
cell barrier lining most blood vessels. After
genes reach the correct tissues, they must pass
across cell membranes and enter the cells’ nu-
cleus. This is no easy step as cells have de-
signed efcient mechanisms for processing ex-
ogenous molecules. Once cells take up macro-
molecules, these are generally digested within
lysosomes within the cells.16
Animal and human studies have shown that
relatively efcient gene expression can be
achieved by direct injection of a gene into mus-
cle.17-19 Muscle cells appear able to take up
exogenous genes and produce the protein from
the gene. However, direct injection of naked
(uncoated) DNA has generally been less suc-
cessful in other tissues. Furthermore, direct
injection is invasive and technically difcult to
achieve in some tissues such as the heart. A
variety of coating materials has been tested to
improve delivery of genetic materials. These
include liposomes, cationic (positively charged
polymers), and viruses.20-27 Some viruses have
evolved over millions of years for delivering
genetic materials into living cells. Some stud-
ies have shown that viruses are efcient gene
delivery vectors, that is, high levels of gene
expression can be achieved using viruses to
deliver genes. Immune response to virus can
limit the effectiveness of gene therapy with a
viral vector.28 Viruses are antigenic and can
cause allergic reactions. A death occurred in
one recent clinical trial of gene therapy using a
viral vector, and this may have been due to an
immune reaction related to the viral vector.29
Additionally, there is a concern about mu-
tagenesis with some of the viral vectors.30 Cur-
rently there is a need for safe synthetic vectors,
which might be delivered intravenously to pro-
vide targeted gene delivery to a localized tis-
sue.
Given the need for new, effective gene deliv-
ery vectors and the barriers to their develop-
ment, how might ultrasound contrast agents
ll this role? Ultrasound contrast agents can be
designed as safe vehicles for encapsulating ge-
netic materials.31 Ultrasound energy can be
used to cavitate (rupture) ultrasound contrast
agents and deliver genes locally to a tissue.32
Cavitation can be exploited to increase trans-
vascular passage of macromolecules and cellu-
lar uptake or passage of therapeutic agents.33,34
Ultrasound contrast agents can also be targeted
to cell-specic receptors to hone in on a target,
and ultrasound can then be applied to improve
uptake of the genetic material.
In our assessment (ImaRx Therapeutics,
Inc., Tucson, AZ, USA) of the potential of ul-
trasound contrast agents as gene delivery ve-
hicles, we rst performed studies of the effects
of ultrasound alone on gene expression in cell
culture.35 Cells were exposed to ultrasound us-
ing a 1.0-megahertz continuous wave probe
(RichMar, Inola, OK, USA) by immersing the
head of the transducer directly into the cell
culture medium overlying the cells. The effect
of ultrasound exposure on the temperature of
the cell culture medium was assessed. Cell sur-
vival studies were performed to study the ef-
fects of different levels of ultrasound power as
well as the duration of insonation on cell sur-
vival. Transfection studies were performed us-
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ing marker genes, which do not exert a thera-
peutic effect such as p-chloramphenicolacetyl-
transferase (CAT), beta-galactosidase (GAL),
and green uorescent protein (GFP) in several
different cell lines such as HeLa, NIH t-3, and
COS-1 cells. Figure 1 shows typical results
from these studies. Ultrasound without micro-
bubbles increased the gene expression in all of
these cell lines. The enhancement of transfec-
tion occurred at levels of ultrasound of about
0.5 W/cm2 and duration of exposure of only
about 15 seconds and did not appreciably heat
the cells nor adversely affect their survival. We
extended these experiments in vivo into nude
mice implanted with human melanomas. The
tumors of these mice were injected with the
gene for interleukin-2 (IL-2) using a lipid vec-
tor—in this case not a microbubble. The ani-
mals were sacriced 72 hours later, the tumors
excised, and the cells obtained from the tumor
and then grown in cell culture. As shown in
Figure 2, ultrasound increased gene expression
in the tumors.
To try to understand the mechanism respon-
sible for the enhancement of gene expression in
cells with ultrasound, we analyzed gene ex-
pression in cells exposed to ultrasound using a
cell culture model.36 We found that ultrasound
upregulated the expression of a number of cell
repair genes. It could be that this upregulation
of gene expression enhances the expression of
exogenous genes as well. It also could be that
mechanical factors (e.g., cell permeability, etc.)
are also important.
While ultrasound contrast agents are used
diagnostically to reect sound, in gene therapy
they may also be used to increase absorption of
sonic energy. Ultrasound contrast agents are
mainly based on microbubbles.37 Microbubbles
are elastic and compressible, have a much
lower density than water, and create an acous-
tic impedance mismatch from biological tissues
and uids.38 Because of these properties, mi-
crobubbles are efcient reectors of ultra-
sound, and hence useful as ultrasound contrast
agents. Microbubbles also lower the threshold
of energy for cavitation.39 In cavitation, ultra-
sound energy is concentrated into a microdo-
main.40 Cavitation creates small shock waves,
which will increase cell permeability. Cavita-
tion destroys the microbubbles and can be used
to release materials entrapped within the mi-
crobubbles or coated onto the surface of the
microbubbles. Microbubbles and other materi-
als (e.g., gaseous precursors that convert to gas
at a temperature close to 37°C) that have suf-
ciently different acoustic impedance from tis-
sues and biological uids may be referred to as
acoustically active. Such materials can be used
to increase the absorption of acoustic energy
within the tissue or blood to cause local thera-
peutic effects.
Figure 3 shows the effects of cavitation on
microvascular permeability.41 As microbubbles
are cavitated by ultrasound, the local shock
waves increase capillary permeability. This
process has been shown experimentally to in-
crease transcapillary passage of macromole-
cules or nanospheres codelivered with the mi-
crobubbles.41,42 Microvascular permeabiliza-
Figure 1. The effects of SonoPoration on transfection
rates of mammalian cells. In these experiments, the plas-
mid for chloramphenicolacetyltransferase (CAT) gene with
a liposome vector was administered to three different mam-
malian cell lines (HeLa, C-127, and NIH/3T3). Ultrasound
energy was applied to the cells and CAT gene expression
was measured 48 hours later using CAT assay. As shown in
the gure, ultrasound has a dramatic effect on increasing
the efciency of transfection. Of note, the NIH/3T3 cells,
which were the most difcult to transfect without ultra-
sound, showed the largest effective increase in transfection
efciency.
Figure 2. The effect of ultrasound on gene therapy of mice
tumors. In these experiments, the gene for the cytokine,
interleukin 2 (IL-2) was injected into the tumor using a
lipid carrier (DMRIE:DOPE). Ultrasound caused a sever-
alfold increase in gene expression in the tumors, resulting
in increased production of IL-2 in the tumor.
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tion caused by cavitation of microbubbles may
be an important mechanism for gene delivery
with ultrasound contrast agents. Experimental
studies by Dr. Sanjiv Kaul’s group at the Uni-
versity of Virginia show that capillary perme-
ability effects occur in experimental animals
with microbubbles using a diagnostic ultra-
sound transducer and a mechanical index of
about 1.6 megapascals.41,42
Microbubbles with a cationic surface have
been produced by ImaRx Therapeutics, Inc., to
bind genetic materials (Fig. 4). These micro-
bubbles avidly bind DNA.43 Applications of ul-
trasound energy in the range of 1 megapascals
rupture the microbubbles and release the
Figure 3. The effects of cavitation on microvascular per-
meability. Nanospheres and drugs can be delivered into the
interstitium as the microbubbles cavitate. This process can
be used to improve local drug delivery. Black arrows indi-
cate gaps formed between the capillary endothelial cells by
the energy of cavitation. (Adapted from reference 41)
Figure 4. DNA/microbubble interaction. Using electro-
static interaction, genetic material may be bound nonco-
valently to the surface of microbubbles.
Figure 5. Liquid peruorocarbon gene carrier. The outer
surface is stabilized by amphipathic lipid. Targeting li-
gands have been incorporated onto the head groups of the
lipids. The genetic material is stabilized by cationic lipids.
Electron microscopy studies have shown that the DNA is
condensed as an electron-dense granule within the center of
the nanoparticle. The diameter of these particles is about
100-200 nanometers.
Figure 6. Schematic diagram of gene therapy to the
heart. A diagnostic ultrasound transducer is placed on the
patient’s chest. An ultrasound contrast agent bearing ge-
netic material has been administered intravenously. As the
microbubbles enter the region of insonation they distribute
within the myocardial tissue via the vascular bed. The
microbubbles cavitate within the capillaries of the myocar-
dial tissue releasing the genetic material.
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DNA. Using gel electrophoresis, we have
shown that the DNA is intact and stable after
cavitation with ultrasound and release of the
DNA from the microbubbles. Dr. Thomas Por-
ter of the University of Nebraska has also
shown that albumin-coated peruorobutane
microbubbles will bind oligonucleotides.44-47
Dr. Fuminori Moriyasu’s group at the Univer-
sity of Kyoto has prepared cationic gelatin-
coated gas-lled polymeric microspheres and
shown that these will bind genetic materials.48
In addition to the microbubbles shown in Fig-
ure 4, ImaRx Therapeutics, Inc., has produced
gaseous precursor materials for gene delivery
using phospholipids and peruorocarbons such
as peruorohexane and peruoropentane. As
shown in Figure 5, the structure of these
agents is different from the microbubbles. Elec-
tron microscopy studies have been performed
and showed that the DNA is entrapped in the
center of the uorocarbon material and con-
densed into small electron dense structures
within uorocarbon cores. These agents, like
the microbubbles, have different acoustic im-
pedance from water and can be used to absorb
ultrasound energy as cavitation nuclei. As
shown in Figure 5, targeting ligands have also
been incorporated onto the surface of these gas-
eous precursor agents. Fibroblast growth fac-
tor (FGF) has been covalently bound to lipids
coating the surface of these agents. FGF is a
biologically important ligand, expressed on en-
dothelial cells in angiogenesis associated with
cancer as well as atherosclerosis. In vitro
transfection studies in cell culture using cells
expressing the FGF receptor have shown sig-
nicant enhancement of gene expression from
uorocarbon vectors bearing the FGF ligand.
In vivo studies have been performed in rats
with intravenous injection of microbubbles as
well as gaseous precursor agents binding
genes. Most studies have been performed using
marker genes, that do not exert a therapeutic
effect such as p-chloramphenicol acetyl trans-
ferase (CAT), beta-galactosidase (b-GAL), and
green uorescent protein. When gene-carrying
microbubbles are injected IV and ultrasound is
applied to the animal’s thigh, preferential gene
expression is attained in the muscle of in-
sonation (ImaRx Therapeutics, Inc.).31 Very
low levels of gene expression are observed in
animals administered these agents unless they
are insonated by ultrasound. Moriyasu’s group
has administered cationic gelatin-coated mi-
crosphere agents binding the CAT gene IV to
rats and applied ultrasound to the animals’
livers. High gene expression was achieved in
the liver of the animals exposed to ultrasound
but minimal, if any, expression in animals ad-
ministered the agents but not exposed to ultra-
sound.48 Thomas Porter has administered al-
bumin-coated microbubbles binding oligonucle-
otides encoding the antisense sequence to FGF.
In these experiments, the antisense construct
to FGF is designed to decrease broblast pro-
liferation. Arterial injury was created in the
pig model, and the antisense carrying micro-
bubbles were administered intravascularly
and ultrasound was applied to the region of
arterial damage. Porter was able to demon-
strate deposition of antisense material in the
vessel wall in the region of insonation by ultra-
sound.45 Decreased broblast proliferation was
observed in the region of insonation presum-
ably due to inhibition of FGF by the antisense
oligonucleotides.44
We have performed cardiac experiments for
gene delivery at the University of Michigan.
Cationic phospholipid-coated peruorobutane
microbubbles were prepared to bind the CAT
gene. The DNA was added to the preformed
microbubbles, agitated gently and the DNA
was bound by the microbubbles. The mean size
of the microbubbles was about 2-microns. The
material was administered via peripheral vein
and ultrasound was applied to the animal’s
heart using a 1.0 megahertz transducer with a
Sonos Model 5500 ultrasound system and an
insonation energy level of 1.7 MegaPascals as
shown in Figure 6. The dog was sacriced 48
hours after the gene delivery experiment, the
heart was excised, and CAT gene expression
assayed. High CAT levels were observed within
the myocardium within the region of in-
sonation, but not within the myocardium not
exposed to ultrasound.49
Conclusions
Ultrasound has a direct effect on gene ex-
pression that may be used to enhance gene
expression without the use of exogenous micro-
bubbles. A synergistic effect is attained with
the use of microbubbles and ultrasound and
cavitation is a likely mechanism. Acoustically
active materials, microbubbles, and gaseous
precursor agents have been developed that
bind or entrap genetic materials. Targeting li-
gands have also been incorporated onto the
surface of these agents for cell-specic delivery.
Acoustically active gene delivery vehicles ap-
pear to hold promise for gene delivery. These
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materials can be injected IV and targeted gene
delivery is attained within the tissue exposed
to ultrasound. Myocardial targeted gene deliv-
ery has been shown from IV injection of gene-
carrying microbubbles in concert with cardiac
ultrasound. This new technology holds the
promise to deliver genes more selectively than
other methods and less invasively than direct
injection. Studies are currently in progress
with therapeutic genes in experimental ani-
mals. Successful clinical development of ultra-
sound-mediated gene delivery with acousti-
cally active carriers will entail additional ex-
perimental studies as well as clinical trials.
The ability to focus ultrasound and cause local
cavitation with these new gene carriers may
provide a powerful new tool for gene delivery.
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